DBV Technologies S.A. (DBVT)
$
22.76
+1.24 (5.45%)
Key metrics
Financial statements
Free cash flow per share
-0.6588
Market cap
712.8 Million
Price to sales ratio
305.1457
Debt to equity
0.0962
Current ratio
2.4530
Income quality
0.7212
Average inventory
0
ROE
-2.8715
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
DBV Technologies S.A. is a clinical-stage biopharmaceutical company engaged in the research and development of epicutaneous immunotherapy products. Its lead product candidate, Viaskin Peanut, has successfully completed Phase III clinical trials for the treatment of peanut allergies in children aged 4 to 11, as well as in adolescents and adults. Additionally, the company is advancing Viaskin Milk, which is currently in Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA). Viaskin Egg is in the pre-clinical stage aimed at addressing hen's egg allergy, while the company is also developing a booster vaccine for Bordetella pertussis. Other early-stage research programs are focused on potential vaccines for respiratory syncytial virus, as well as treatments targeting Crohn's disease, celiac disease, and type I diabetes. DBV Technologies has formed a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test designed for diagnosing non-IgE mediated CMPA in infants and toddlers. The company's financial performance reflects a nuanced complexity; it earned an interest income of $2,726,000.00 showcasing its financial investments, while the gross profit ratio stands at 0.00 reflecting the efficiency of its production and sales operations. The EBITDA ratio is 0.00 highlighting the operational efficiency of the organization, and the diluted EPS is -$5.90 accounting for potential share dilution. Furthermore, the total costs and expenses for the company are $120,526,718.00 reflecting its overall spending in the biopharmaceutical sector. In the context of its market presence, the stock of DBV Technologies is affordable at $9.50 making it suitable for budget-conscious investors. With an average trading volume of 337,358.00 the stock indicates moderate liquidity, allowing investors to engage with the company without excessive market impact. With a market capitalization of $544,458,780.00 DBV Technologies is classified as a small-cap player within its field. It serves as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth as it belongs to the Healthcare sector. This positioning underscores its importance and potential impact on advancements in biopharmaceutical research and development.
Is DBV Technologies S.A. (DBVT) a good investment?
Investing in DBV Technologies S.A. (DBVT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is DBV Technologies S.A. (DBVT)'s stock forecast?
Analysts predict DBV Technologies S.A. stock to fluctuate between $2.93 (low) and $26.19 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is DBV Technologies S.A.'s market capitalization?
As of 2025-12-19, DBV Technologies S.A.'s market cap is $544,458,780, based on 23,921,739 outstanding shares.
How does DBV Technologies S.A. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., DBV Technologies S.A. has a Lower Market-Cap, indicating a difference in performance.
How can I buy DBV Technologies S.A. (DBVT) stock?
To buy DBV Technologies S.A. (DBVT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DBVT. Place an order (Market, Limit, etc.).
What is the best time to invest in DBV Technologies S.A.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has DBV Technologies S.A. stock ever split?
DBV Technologies S.A.'s last stock split was 1:5 on 2024-11-29.
How did DBV Technologies S.A. perform in the last earnings report?
Revenue: $0 | EPS: -$5.90 | Growth: 55.26%.
Where can I find DBV Technologies S.A.'s investor relations reports?
Visit https://www.dbv-technologies.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for DBV Technologies S.A.?
You can explore historical data from here
What is the all-time high and low for DBV Technologies S.A. stock?
All-time high: $59.90 (2021-08-31) | All-time low: $2.20 (2024-11-19).
What are the key trends affecting DBV Technologies S.A. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
globenewswire.com
Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company's Phase 3 VITESSE clinical trial of the VIASKIN® Peanut patch in peanut allergic children aged 4-7 years. With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year.
globenewswire.com
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts.
globenewswire.com
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr.
zacks.com
Here is how DBV Technologies S.A. (DBVT) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
globenewswire.com
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025.
globenewswire.com
Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled “Harnessing Immune Plasticity to Alter the Path of Food Allergy”.
globenewswire.com
Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $30 million, before deducting sales agent commissions and offering expenses payable by the Company, to Artisan Partners Limited Partnership (“Artisan”) through Citizens Capital Markets, acting as sales agent. Each ADS represents the right to receive five Ordinary Shares of the Company.
globenewswire.com
Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $30 million, before deducting sales agent commissions and offering expenses payable by the Company, to Invus (“Invus”) through Citizens Capital Markets, acting as sales agent. Each ADS represents the right to receive five Ordinary Shares of the Company.
globenewswire.com
Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV's management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Rosen, Chairman of the Board.
See all news
